• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Inhibition of human B-cell lymphoma growth by CD40 stimulation.

作者信息

Funakoshi S, Longo D L, Beckwith M, Conley D K, Tsarfaty G, Tsarfaty I, Armitage R J, Fanslow W C, Spriggs M K, Murphy W J

机构信息

Laboratory of Leukocyte Biology, NCI-FCRDC, MD 21702-1201.

出版信息

Blood. 1994 May 15;83(10):2787-94.

PMID:7514045
Abstract

CD40 is a molecule present on B lymphocyte lineage cells that is important in B-cell differentiation and activation. Signaling through CD40 has been shown to exert costimulatory signals on normal B cells resulting in proliferative and differentiation responses. Examination of several B-cell lymphomas showed cell-surface expression of the CD40 molecule. Incubation of these lymphomas with anti-CD40 antibodies resulted in significant growth inhibition in vitro. Cross-linking of the CD40 antibodies resulted in even greater inhibition of proliferation. A recombinant soluble human CD40 ligand was also shown to inhibit lymphoma proliferation. When various human B-cell lymphomas were transferred into mice with severe combined immune deficiency, the treatment of the mice with anti-CD40 antibodies resulted in significant increases in survival showing that anti-CD40 is efficacious after in vivo administration. Thus, CD40 stimulation by either the antibody or soluble ligand directly inhibits human B-cell lymphoma growth and therefore, may be of significant clinical use in their treatment.

摘要

相似文献

1
Inhibition of human B-cell lymphoma growth by CD40 stimulation.
Blood. 1994 May 15;83(10):2787-94.
2
Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.在给予人外周血淋巴细胞的严重联合免疫缺陷小鼠中,抗CD40抗体可预防爱泼斯坦-巴尔病毒介导的人B细胞淋巴瘤发生。
Blood. 1995 Sep 1;86(5):1946-53.
3
Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.CD40刺激在预防人类EB病毒淋巴瘤发生中的作用。
Leuk Lymphoma. 1997 Jan;24(3-4):187-99. doi: 10.3109/10428199709039007.
4
Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.抗CD40和抗CD20单克隆抗体介导的针对人B细胞淋巴瘤的体外和体内抗肿瘤作用差异
J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):93-101. doi: 10.1097/00002371-199603000-00002.
5
Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells.针对小鼠CD40的抗体可刺激正常B淋巴细胞,但抑制B淋巴瘤细胞的增殖。
Cell Immunol. 1993 Dec;152(2):468-80. doi: 10.1006/cimm.1993.1305.
6
T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.用可溶性CD40配体预处理淋巴瘤细胞可增强抗CD3×抗B细胞淋巴瘤单克隆抗体诱导的T细胞活化。
Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):174-9. doi: 10.1007/s002620050426.
7
Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention.源自人外周血淋巴细胞-严重联合免疫缺陷嵌合小鼠的爱泼斯坦-巴尔病毒诱导的人B细胞淋巴瘤:特征及CD40刺激在其治疗和预防中的作用
Pathobiology. 1995;63(3):133-42. doi: 10.1159/000163944.
8
Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.可溶性重组人CD40配体对人乳腺癌生长的抑制作用
Blood. 1999 May 1;93(9):2999-3007.
9
Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest.针对小鼠CD40的抗体可保护正常和恶性B细胞免于诱导性生长停滞。
Cell Immunol. 1994 Jul;156(2):272-85. doi: 10.1006/cimm.1994.1174.
10
Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin.在CD40与CD19、CD20、CD95或表面免疫球蛋白连接后,人B细胞淋巴瘤增殖的抑制作用增强。
Immunopharmacology. 1996 Nov;35(2):129-39. doi: 10.1016/s0162-3109(96)00138-5.

引用本文的文献

1
CD8 T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells.CD8 T细胞衍生的CD40L介导表达CD40的癌细胞中的非经典细胞毒性。
Sci Adv. 2025 May 23;11(21):eadr9331. doi: 10.1126/sciadv.adr9331. Epub 2025 May 21.
2
Soluble CD40 Ligand as a Promising Biomarker in Cancer Diagnosis.可溶性 CD40 配体作为癌症诊断中有前途的生物标志物。
Cells. 2024 Jul 28;13(15):1267. doi: 10.3390/cells13151267.
3
Dendritic cell subsets and implications for cancer immunotherapy.树突状细胞亚群及其在癌症免疫治疗中的意义。
Front Immunol. 2024 Jun 5;15:1393451. doi: 10.3389/fimmu.2024.1393451. eCollection 2024.
4
Harnessing the potential of CD40 agonism in cancer therapy.利用CD40激动作用在癌症治疗中的潜力。
Cytokine Growth Factor Rev. 2024 Feb;75:40-56. doi: 10.1016/j.cytogfr.2023.11.002. Epub 2023 Dec 4.
5
Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses.利用 Hu-PBL 小鼠研究人类局限性病毒的发病机制。
Viruses. 2023 Jan 13;15(1):228. doi: 10.3390/v15010228.
6
Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis.整合素作为 CD154 受体的新功能:在炎症和细胞凋亡中的作用。
Cells. 2022 May 25;11(11):1747. doi: 10.3390/cells11111747.
7
Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.新型靶向 mtLivin 纳米颗粒治疗弥漫性大 B 细胞淋巴瘤。
Oncogene. 2021 Jan;40(2):334-344. doi: 10.1038/s41388-020-01529-z. Epub 2020 Oct 30.
8
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.CD40/CD40L 免疫检查点的分子基础和治疗意义。
Pharmacol Ther. 2021 Mar;219:107709. doi: 10.1016/j.pharmthera.2020.107709. Epub 2020 Oct 20.
9
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.激动性抗CD40抗体治疗恶性肿瘤的特性及临床试验结果
Oncol Lett. 2020 Nov;20(5):176. doi: 10.3892/ol.2020.12037. Epub 2020 Aug 31.
10
Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect.在癌症免疫治疗中靶向 APC 激活以增强远隔效应。
Front Immunol. 2019 Apr 2;10:604. doi: 10.3389/fimmu.2019.00604. eCollection 2019.